Antibiotic

ViaClean Technologies Offers To Safeguard American Icons By Donating Revolutionary BIOPROTECTUs™ System

Thursday, September 17, 2020 - 6:13pm

The announcement was made this week by Greg Tipsord, President and Chief Executive Officer of ViaClean Technologies.

Key Points: 
  • The announcement was made this week by Greg Tipsord, President and Chief Executive Officer of ViaClean Technologies.
  • To support the nation's reopening of the country, ViaClean Technologies is in discussion with some of America's most beloved landmarks to donate its revolutionary BIOPROTECTUsSystem.
  • As part of this promise, ViaClean will reapply the BIOPROTECTUsSystem every 90 days in order to continuously safeguard.
  • ViaClean Technologies' pioneering and proprietary technologies, products and services provide antibacterial, antimicrobial, disinfectant and advanced odor control solutions for commercial, institutional and consumer use.

Global Direct-Fed Microbials (Dry & Liquid) Market 2019-2020 & 2028 - Rise in Concerns Regarding Use of Antibiotics in Animals - ResearchAndMarkets.com

Thursday, September 17, 2020 - 3:31pm

There is an increasing consumption of animal products like milk and meat across the world, which is primarily driving the global market.

Key Points: 
  • There is an increasing consumption of animal products like milk and meat across the world, which is primarily driving the global market.
  • The growing usage of direct-fed microbials in animal production to enhance nutrient absorption among the animals is improving its profitability.
  • In addition, there are rising concerns over the use of antibiotics in animals.
  • The ban on the use of antibiotics in the European countries has proved beneficial to the direct-fed microbials market growth in the region.

Venatorx Pharmaceuticals Names William Sargent Senior Vice President, Commercial Strategy

Thursday, September 17, 2020 - 3:00pm

Venatorx Pharmaceuticals today announced that Will Sargent has joined the Company as Senior Vice President, Commercial Strategy.

Key Points: 
  • Venatorx Pharmaceuticals today announced that Will Sargent has joined the Company as Senior Vice President, Commercial Strategy.
  • View the full release here: https://www.businesswire.com/news/home/20200917005087/en/
    William Sargent Jr. - Senior Vice President, Commercial Strategy at Venatorx Pharmaceuticals, Inc. (Photo: Business Wire)
    Will has a proven track record of success and extensive expertise across a wide array of therapeutic areas, most notably in antibiotics, said Christopher J. Burns, Ph.D. , President and CEO of Venatorx.
  • Prior to joining Venatorx, Mr. Sargent served as Vice President, Commercial Strategy at Nabriva where he led the launch and commercialization for Xenleta, a novel antibiotic approved for the treatment of community acquired bacterial pneumonia (CABP).
  • Before Auxilium, Mr. Sargent was a biotechnology equities analyst at Bank of America and held multiple commercial roles at Amgen and Immunex.

North America Oral Antibiotics Markets Forecast to 2030 with Covid-19 Impact Analysis

Thursday, September 17, 2020 - 12:15pm

North America oral antibiotics market is expected to grow by 2.8% annually in the forecast period and reach $6,122.9 million by 2030 driven by rising complications associated with COVID-19 epidemic, development of innovative antibiotics, and growing healthcare expenditure.

Key Points: 
  • North America oral antibiotics market is expected to grow by 2.8% annually in the forecast period and reach $6,122.9 million by 2030 driven by rising complications associated with COVID-19 epidemic, development of innovative antibiotics, and growing healthcare expenditure.
  • The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year.
  • The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19.
  • Specifically, potential risks associated with investing in North America oral antibiotics market are assayed quantitatively and qualitatively through a Risk Assessment System.

Global Antibiotics Market- Featuring Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, and Bayer AG, Among Others | Technavio

Wednesday, September 16, 2020 - 11:30pm
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20200916005835/en/
    Technavio has announced its latest market research report titled Global Antibiotics Market 2020-2024.
  • (Graphic: Business Wire)
    The report on the antibiotics market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.
  • The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment.
  • Download Free Sample Report on COVID-19 Recovery Analysis
    The antibiotics market analysis includes the application segment, product segment, drug origin segment, action mechanism segment, and geographic landscapes.

Scientists from NUST MISIS: Boron nitride nanofilms will replace antibiotics while protecting against bacterial and fungal infections

Monday, September 14, 2020 - 9:00am

MOSCOW, Sept. 14, 2020 /PRNewswire/ -- NUST MISIS material scientists have presented antibacterial nano-coatings based on boron nitride, which are highly effective against microbial pathogens (up to 99.99%).

Key Points: 
  • MOSCOW, Sept. 14, 2020 /PRNewswire/ -- NUST MISIS material scientists have presented antibacterial nano-coatings based on boron nitride, which are highly effective against microbial pathogens (up to 99.99%).
  • They can become a safe alternative to the usual antibiotics in implantology since they do not have typical negative side effects.
  • Nowadays, due to the significant increase in the number of surgical procedures around the world, scientists are solving the problem of microbial infections caused by implants.
  • The researchers went further and filled the micro-pores of a thin coating of boron nitride with the gentamicin antibiotic.

Scientists from NUST MISIS: Boron nitride nanofilms will replace antibiotics while protecting against bacterial and fungal infections

Monday, September 14, 2020 - 9:00am

MOSCOW, Sept. 14, 2020 /PRNewswire/ -- NUST MISIS material scientists have presented antibacterial nano-coatings based on boron nitride, which are highly effective against microbial pathogens (up to 99.99%).

Key Points: 
  • MOSCOW, Sept. 14, 2020 /PRNewswire/ -- NUST MISIS material scientists have presented antibacterial nano-coatings based on boron nitride, which are highly effective against microbial pathogens (up to 99.99%).
  • They can become a safe alternative to the usual antibiotics in implantology since they do not have typical negative side effects.
  • Nowadays, due to the significant increase in the number of surgical procedures around the world, scientists are solving the problem of microbial infections caused by implants.
  • The researchers went further and filled the micro-pores of a thin coating of boron nitride with the gentamicin antibiotic.

Armata Pharmaceuticals Announces Participation in Upcoming Investor Conferences

Friday, September 11, 2020 - 12:30pm

MARINA DEL REY, Calif., Sept. 11, 2020 /PRNewswire/ --Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that management will be participating in two upcoming investor conferences.

Key Points: 
  • MARINA DEL REY, Calif., Sept. 11, 2020 /PRNewswire/ --Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that management will be participating in two upcoming investor conferences.
  • Armata is a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology.
  • Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens.
  • Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.

Poor home hygiene contributing to antibiotic resistance, warn global hygiene experts

Friday, September 11, 2020 - 12:01am

In a new Position Paper developed by the GHC and published in the September edition of the American Journal of Infection Control,the experts set out the evidence showing that better hygiene in our homes and everyday lives plays an essential part in tackling antibiotic resistance.

Key Points: 
  • In a new Position Paper developed by the GHC and published in the September edition of the American Journal of Infection Control,the experts set out the evidence showing that better hygiene in our homes and everyday lives plays an essential part in tackling antibiotic resistance.
  • Good hygiene contributes to the fight against AMR in two ways, by preventing infection, thereby reducing the need for antibiotic prescribing and preventing person to person spread of infections which are antibiotic resistant.
  • The paper reviews evidence that to minimise the spread of infections in home and community settings, a more focused approach to hygiene based on risk assessment is needed.
  • View original content to download multimedia: http://www.prnewswire.com/news-releases/poor-home-hygiene-contributing-t...

Poor home hygiene contributing to antibiotic resistance, warn global hygiene experts

Friday, September 11, 2020 - 12:01am

In a new Position Paper developed by the GHC and published in the September edition of the American Journal of Infection Control,the experts set out the evidence showing that better hygiene in our homes and everyday lives plays an essential part in tackling antibiotic resistance.

Key Points: 
  • In a new Position Paper developed by the GHC and published in the September edition of the American Journal of Infection Control,the experts set out the evidence showing that better hygiene in our homes and everyday lives plays an essential part in tackling antibiotic resistance.
  • Good hygiene contributes to the fight against AMR in two ways, by preventing infection, thereby reducing the need for antibiotic prescribing and preventing person to person spread of infections which are antibiotic resistant.
  • The paper reviews evidence that to minimise the spread of infections in home and community settings, a more focused approach to hygiene based on risk assessment is needed.
  • For example, removing infection-spreading germs from high-risk surfaces and hands at critical times, such as when preparing food and using the toilet, has been proven to minimise the spread of infections from person to person.